Image via Endpoints News
Incyte: Ma Activity
Incyte acquiring Vega Therapeutics (Star Therapeutics' subsidiary) for $1.25B upfront plus up to $750M in milestone payments. Vega has Phase 3 bleeding disorder candidate.
Source: Endpoints News
The leadership read
Will need clinical development leads, regulatory affairs specialists, integration managers, and commercial launch team for bleeding disorder indication. R&D talent to advance Phase 3 program.
Market context: the MitchelLake Talent Market Index reads 108.5 — Hot (+10.8 vs prior month); EMEA signal share is steady (-1.2pts).
MitchelLake in this thematic
Our work · 2025
Growth Marketing Lead
Habacus
EMEA · Technology · growth · education finance
Our work · 2023
Board Appointment
JPMorgan European Growth and Income PLC
EMEA · Fintech · board · growth
Our work · 2022
Chief Marketing Officer
Global Message Services AG
EMEA · AI, Data & Enterprise Software · c-suite · growth